AMLX Amylyx Pharmaceuticals, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$18.5

Period return

+2.27 (+13.99%)

Volume

2.7M

2026-07-21O $17.52 H $18.86 L $17.51 C $18.5MA5 $17.7MA20 $17.79MA60 $15.68MA120 $15.29

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 04. 28.LowBUY3 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2026. 03. 25.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 19.LowBUY4 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 03. 05.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 03.MediumBUY5 months ago
Stifel: Buy
US analyst rating / recommendation change.
2026. 02. 20.LowBUY5 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 02. 10.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $23.4 · 10 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: Cambridge, MA, United States
Fiscal year end: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.35	—	—	$0	—	Scheduled
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-3.89	—	—	$88.04M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-2.82	—	—	$87.62M	Reported
FY2025 Q1	2024. 03. 31.	Time TBD	—	$-1.75	—	—	$88.64M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	344,401	$4.16M	0.01%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	335,000	$4.05M	0.01%	—	New position
3	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	161,945	$2.25M	0.00%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	106,535	$1.48M	0.00%	—	New position

Amylyx Pharmaceuticals, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 28.	Mizuho	—	Maintain	Outperform → Outperform	—	Mizuho: Outperform
2026. 03. 25.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 19.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 03. 05.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 03.	Stifel	—	Initiate coverage	— → Buy	—	Stifel: Buy
2026. 02. 20.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy